Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 10


Clinical significance of phenotyping and karyotyping of circulating tumor cells in patients with advanced gastric cancer.

Li Y, Zhang X, Ge S, Gao J, Gong J, Lu M, Zhang Q, Cao Y, Wang DD, Lin PP, Shen L.

Oncotarget. 2014 Aug 30;5(16):6594-602.


V-ATPase inhibition overcomes trastuzumab resistance in breast cancer.

von Schwarzenberg K, Lajtos T, Simon L, Müller R, Vereb G, Vollmar AM.

Mol Oncol. 2014 Feb;8(1):9-19. doi: 10.1016/j.molonc.2013.08.011. Epub 2013 Sep 5.


Current status of anti-human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistance.

Chung A, Cui X, Audeh W, Giuliano A.

Clin Breast Cancer. 2013 Aug;13(4):223-32. doi: 10.1016/j.clbc.2013.04.001. Review.


Aptamers from cell-based selection for bioanalytical applications.

Tan W, Donovan MJ, Jiang J.

Chem Rev. 2013 Apr 10;113(4):2842-62. doi: 10.1021/cr300468w. Epub 2013 Mar 19. Review. No abstract available.


Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment.

Giuliano M, Giordano A, Jackson S, Hess KR, De Giorgi U, Mego M, Handy BC, Ueno NT, Alvarez RH, De Laurentiis M, De Placido S, Valero V, Hortobagyi GN, Reuben JM, Cristofanilli M.

Breast Cancer Res. 2011 Jun 15;13(3):R67. doi: 10.1186/bcr2907.


Primary trastuzumab resistance: new tricks for an old drug.

Wilken JA, Maihle NJ.

Ann N Y Acad Sci. 2010 Oct;1210:53-65. doi: 10.1111/j.1749-6632.2010.05782.x.


Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics.

Wilken JA, Webster KT, Maihle NJ.

J Ovarian Res. 2010 Mar 27;3:7. doi: 10.1186/1757-2215-3-7.


Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours.

Gelardi T, Damiano V, Rosa R, Bianco R, Cozzolino R, Tortora G, Laccetti P, D'Alessio G, De Lorenzo C.

Br J Cancer. 2010 Feb 2;102(3):513-9. doi: 10.1038/sj.bjc.6605499. Epub 2010 Jan 5.


Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family.

Shepard HM, Brdlik CM, Schreiber H.

J Clin Invest. 2008 Nov;118(11):3574-81. doi: 10.1172/JCI36049. Review.

Supplemental Content

Support Center